Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-directed CAR T-cell Therapy”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07659704
What this trial is testing

CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus

Who this might be right for
Lupus Erythematosus, Systemic
University of Sao Paulo 16
Very early researchLooking for participantsNCT07350837
What this trial is testing

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

Who this might be right for
Highly Sensitized Patients Awaiting Kidney Transplant
Tongji Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT04544592
What this trial is testing

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell Non Hodgkin Lymphoma
University of Colorado, Denver 45
Testing effectiveness (Phase 2)Looking for participantsNCT06101381
What this trial is testing

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

Who this might be right for
Leukemia, Acute LymphoblasticLymphoma, Non-Hodgkin
University of Sao Paulo 81
Testing effectiveness (Phase 2)UnknownNCT02537977
What this trial is testing

CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Who this might be right for
LeukemiaLymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine 60
Early research (Phase 1)Looking for participantsNCT04892277
What this trial is testing

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+5 more
Mayo Clinic 25
Early research (Phase 1)UnknownNCT03463928
What this trial is testing

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

Who this might be right for
B Cell Leukemia
Chinese PLA General Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT04792489
What this trial is testing

DALY II USA/ MB-CART2019.1 for DLBCL

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more
Miltenyi Biomedicine GmbH 315
Testing effectiveness (Phase 2)Looking for participantsNCT05667506
What this trial is testing

CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd. 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT02028455
What this trial is testing

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Who this might be right for
CD19+ Acute Leukemia
Seattle Children's Hospital 167
Not applicableNot Yet RecruitingNCT06993766
What this trial is testing

The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Who this might be right for
Relapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy
King Faisal Specialist Hospital & Research Center 100
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Large-scale testing (Phase 3)Not Yet RecruitingNCT07735637
What this trial is testing

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
AstraZeneca 750
Testing effectiveness (Phase 2)Ended earlyNCT02935543
What this trial is testing

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Who this might be right for
Leukemia, Acute Lymphoblastic
University of Pennsylvania 1
Early research (Phase 1)WithdrawnNCT05168748
What this trial is testing

CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Early research (Phase 1)WithdrawnNCT06913608
What this trial is testing

Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

Who this might be right for
Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)
Calibr, a division of Scripps Research
Testing effectiveness (Phase 2)Looking for participantsNCT06238648
What this trial is testing

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United 120
Testing effectiveness (Phase 2)WithdrawnNCT05936229
What this trial is testing

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic Leukemia+3 more
Fred Hutchinson Cancer Center
Next Page